Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1
dc.authorid | Saadettin Kılıçkap / 0000-0003-1637-7390 | en_US |
dc.authorscopusid | Saadettin Kılıçkap / 8665552100 | |
dc.authorwosid | Saadettin Kılıçkap / AAP-3732-2021 | |
dc.contributor.author | Bondarenko, I. | |
dc.contributor.author | Sezer, A. | |
dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Gümüş, M. | |
dc.contributor.author | Özgüroğlu, M. | |
dc.contributor.author | Gogishvili, M. | |
dc.contributor.author | urk, H. M. | |
dc.contributor.author | Cicin, I. | |
dc.date.accessioned | 2021-11-15T08:48:00Z | |
dc.date.available | 2021-11-15T08:48:00Z | |
dc.date.issued | 2021 | en_US |
dc.department | İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | [No Abstract Available] | en_US |
dc.identifier.citation | Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., ... & Rietschel, P. (2021). FP04. 03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951. | en_US |
dc.identifier.endpage | S951 | en_US |
dc.identifier.issn | 1556-0864 | en_US |
dc.identifier.issn | 1556-1380 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | S951 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.jtho.2021.08.217 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/2235 | |
dc.identifier.volume | 16 | en_US |
dc.identifier.wos | WOS:000709606500217 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.institutionauthor | Kılıçkap, Saadettin | |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER SCIENCE INC | en_US |
dc.relation.ispartof | JOURNAL OF THORACIC ONCOLOGY | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1 | en_US |
dc.type | Other | en_US |
Dosyalar
Lisans paketi
1 - 1 / 1
Küçük Resim Yok
- İsim:
- license.txt
- Boyut:
- 1.44 KB
- Biçim:
- Item-specific license agreed upon to submission
- Açıklama: